中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

128 records (took 0.026 seconds)

    RESIDENCE STRUCTURES AND RELATED METHODS
    41.
    发明申请
    RESIDENCE STRUCTURES AND RELATED METHODS 审中-公开

    公开(公告)号：US20190125667A1

    公开(公告)日：2019-05-02

    申请号：US16014549

    申请日：2018-06-21

    Applicant: Massachusetts Institute of Technology ,  The Brigham and Women's Hospital, Inc.

    Inventor： Andrew Bellinger ,  Shiyi Zhang ,  Carlo Giovanni Traverso ,  Robert S. Langer ,  Stacy Mo ,  Tyler Grant ,  Mousa Jafari ,  Dean Liang Glettig ,  Angela DiCiccio ,  Omar Abouzid ,  Ameya R. Kirtane

    IPC: A61K9/00 ,  A61K47/32 ,  A61K31/7048 ,  A61K47/34 ,  A61K47/10 ,  A61K31/65

    CPC classification number: A61K9/0065 ,  A61K31/65 ,  A61K31/7048 ,  A61K47/10 ,  A61K47/32 ,  A61K47/34

    Abstract: Residence structures, systems, and related methods are generally provided. Certain embodiments comprise administering (e.g., orally) a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. The residence structure may be, in some cases, a gastric residence structure. In some embodiments, the structures and systems described herein comprise one or more materials configured for high levels of active substances (e.g., a therapeutic agent) loading, high active substance and/or structure stability in acidic environments, mechanical flexibility and strength in an internal orifice (e.g., gastric cavity), easy passage through the GI tract until delivery to at a desired internal orifice (e.g., gastric cavity), and/or rapid dissolution/degradation in a physiological environment (e.g., intestinal environment) and/or in response to a chemical stimulant (e.g., ingestion of a solution that induces rapid dissolution/degradation). In certain embodiments, the structure has a modular design, combining a material configured for controlled release of therapeutic, diagnostic, and/or enhancement agents with a structural material necessary for gastric residence but configured for controlled and/or tunable degradation/dissolution to determine the time at which retention shape integrity is lost and the structure passes out of the gastric cavity. For example, in certain embodiments, the residence structure comprises a first elastic component, a second component configured to release an active substance (e.g., a therapeutic agent), and, optionally, a linker. In some such embodiments, the linker may be configured to degrade such that the residence structure breaks apart and is released from the location internally of the subject after a predetermined amount of time.

    OMNIPHOBIC MATERIALS FOR BIO-APPLICATIONS
    42.
    发明申请
    OMNIPHOBIC MATERIALS FOR BIO-APPLICATIONS 审中-公开

    公开(公告)号：US20170266931A1

    公开(公告)日：2017-09-21

    申请号：US15465304

    申请日：2017-03-21

    Applicant: Massachusetts Institute of Technology ,  The Brigham and Women's Hospital, Inc.

    Inventor： Robert S. Langer ,  Carlo Giovanni Traverso ,  Shiyi Zhang ,  Young-Ah Lucy Lee

    IPC: B32B27/06 ,  B32B3/26

    CPC classification number: B32B27/06 ,  B32B3/26 ,  B32B3/30 ,  B32B5/16 ,  B32B5/30 ,  B32B2255/04 ,  B32B2255/24 ,  B32B2264/02 ,  B32B2264/025 ,  B32B2307/538 ,  B32B2307/70 ,  B32B2535/00

    Abstract: Compositions and articles comprising omniphobic materials for bio-related and other applications are generally provided. In some embodiments, the compositions and articles described herein may be introduced internally of a subject (e.g., in the esophagus, in the gastrointestinal tract, in the rectum). In some aspects, the compositions and articles comprise a releasable therapeutic agent In some embodiments, the compositions and articles described herein may be configured to have a relatively short retention time at the location internal of the subject (e.g., less than 2 seconds) such as a capsule comprising an omniphobic coating. In alternative embodiments, the compositions and articles described herein may be configured to have relative long retention times at the location internal of the subject (e.g., greater than 10 minutes) and include a mucoadhesive portion as well as an omniphobic portion. Such articles may have an omniphobic portion which resists adhesion and/or fouling (e.g., by foodstuffs and/or other materials present internal of the subject) of the article, such that the mucoadhesive portion maintains adhesion to the location internal of the subject for relatively long retention times. In some such embodiments, the article may be a Janus-type device.

    GRAVITY BASED DRUG DELIVERY DEVICE
    48.
    发明公开
    GRAVITY BASED DRUG DELIVERY DEVICE 审中-公开

    公开(公告)号：US20240017045A1

    公开(公告)日：2024-01-18

    申请号：US18031269

    申请日：2021-10-20

    Applicant: Massachusetts Institute of Technology

    Inventor： Carlo Giovanni Traverso ,  Niclas Roxhed ,  Siheng You ,  Graham Arrick ,  Torben Sebastian Last

    IPC: A61M31/00 ,  A61M39/22 ,  A61M5/172

    CPC classification number: A61M31/002 ,  A61M39/22 ,  A61M5/172 ,  A61M2205/33

    Abstract: A drug delivery device may be configured to delivery an active pharmaceutical ingredient (API) to a subject via the subject's oral-gastrointestinal (GI) tract. The drug delivery device may be configured to deliver a payload of an API while within the GI tract of the subject. The drug delivery device may include a reservoir, a potential energy source, a plurality of outlets, and a plurality of valves, wherein each outlet has a corresponding valve. The drug delivery device may further include a sensor configured to sense the direction of gravity, and the valves may be selectively opened based on a sensed direction of gravity. Thus, the drug delivery device may dispense a dose of API within the GI tracts of the subject based at least in part on the sensed direction of gravity.

Patent Agency Ranking